In a report in the Journal of Clinical Oncology, Francois-Xavier Mahon, MD, PhD, and colleagues provided the final analysis of the European Stop Kinase Inhibitors (EURO-SKI)...
In an analysis of two trials (SCOT and IDEA-HORG) reported in the Journal of Clinical Oncology, Domingo et al identified the predictive value of Immunoscore for disease-free...
The composition of the gut microbiome may reveal distinct signatures associated with race, ethnicity, and age of onset in patients with colorectal cancer...
On March 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (Breyanzi), a CD19-directed...
In an analysis of 9-year outcomes of a Chinese trial (ESECC) reported in the Journal of Clinical Oncology, Liu et al found that endoscopic screening for esophageal...
A 5-year community outreach and engagement effort by the Abramson Cancer Center at the University of Pennsylvania to increase enrollment of Black patients into cancer clinical trials more than doubled the percentage of participants, improving access and treatment for a group of patients with...
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
A mathematical tool may help to examine how doctors may coordinate available treatments for high-grade serous ovarian cancer. Published by Gu et al in the Proceedings of the National Academy of Sciences, the new analysis showed that patients who can have complete debulking surgery first, with...
In an updated analysis of the phase III MAIA trial, the addition of daratumumab to lenalidomide and dexamethasone resulted in a statistically significant overall survival benefit over lenalidomide/dexamethasone alone in patients with newly diagnosed multiple myeloma who are ineligible for...
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
As reported in The Lancet Oncology by Arjun V. Balar, MD, and colleagues, the phase II KEYNOTE-057 trial showed that pembrolizumab produced enduring responses in a cohort of patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin (BCG) who were ineligible ...
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...